Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2015 Jul 3

PMID 26137480

Citations 136

Authors

Nirmala Chandralega Kampan

Mutsa Tatenda Madondo

Orla M McNally

Michael Quinn

Magdalena Plebanski

Affiliations

Soon will be listed here.

Abstract

Paclitaxel, a class of taxane with microtubule stabilising ability, has remained with platinum based therapy, the standard care for primary ovarian cancer management. A deeper understanding of the immunological basis and other potential mechanisms of action together with new dosing schedules and/or routes of administration may potentiate its clinical benefit. Newer forms of taxanes, with better safety profiles and higher intratumoural cytotoxicity, have yet to demonstrate clinical superiority over the parent compound.

Citing Articles

Opportunities for Precision Dosing of Cytotoxic Drugs in Non-Small Cell Lung Cancer: Bridging the Gap in Precision Medicine.

Kicken M, Deenen M, van der Wekken A, van den Borne B, van den Heuvel M, Ter Heine R Clin Pharmacokinet. 2025; .

PMID: 40045151 DOI: 10.1007/s40262-025-01492-6.

A novel model of paclitaxel-induced peripheral neuropathy produces a clinically relevant phenotype in mice.

Osborn L, Bishop M, Rodriguez K, Redling D, Duplechain E, Stephens K bioRxiv. 2025; .

PMID: 39990336 PMC: 11844414. DOI: 10.1101/2025.02.10.637458.

A review on green synthesis of silver nanoparticles (SNPs) using plant extracts: a multifaceted approach in photocatalysis, environmental remediation, and biomedicine.

Shahzadi S, Fatima S, Ain Q, Shafiq Z, Janjua M RSC Adv. 2025; 15(5):3858-3903.

PMID: 39917042 PMC: 11800103. DOI: 10.1039/d4ra07519f.

VERU-111, an orally available tubulin inhibitor, suppresses ovarian tumor growth and metastasis.

Waddell S, Zhao G, Liu Z, Chen H, Zhang W, Wang Y J Pharmacol Exp Ther. 2025; 392(1):100006.

PMID: 39893008 PMC: 11808928. DOI: 10.1124/jpet.124.002298.

Functional genomics pipeline identifies CRL4 inhibition for the treatment of ovarian cancer.

Claridge S, Nath S, Baum A, Farias R, Cavallo J, Rizvi N Clin Transl Med. 2025; 15(2):e70078.

PMID: 39856363 PMC: 11761363. DOI: 10.1002/ctm2.70078.

References

Sevko A, Kremer V, Falk C, Umansky L, Shurin M, Shurin G . Application of paclitaxel in low non-cytotoxic doses supports vaccination with melanoma antigens in normal mice. J Immunotoxicol. 2012; 9(3):275-81. DOI: 10.3109/1547691X.2012.655343. View

Manfredi J, Horwitz S . Taxol: an antimitotic agent with a new mechanism of action. Pharmacol Ther. 1984; 25(1):83-125. DOI: 10.1016/0163-7258(84)90025-1. View

Jibodh R, Lagas J, Nuijen B, Beijnen J, Schellens J . Taxanes: old drugs, new oral formulations. Eur J Pharmacol. 2013; 717(1-3):40-6. DOI: 10.1016/j.ejphar.2013.02.058. View

Ferlini C, Cicchillitti L, Raspaglio G, Bartollino S, Cimitan S, Bertucci C . Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009; 69(17):6906-14. DOI: 10.1158/0008-5472.CAN-09-0540. View

Sparreboom A, Wolff A, Verweij J, Zabelina Y, van Zomeren D, McIntire G . Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies. Clin Cancer Res. 2003; 9(1):151-9. View

Rohwer N, Cramer T . Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Updat. 2011; 14(3):191-201. DOI: 10.1016/j.drup.2011.03.001. View

Benedetti Panici P, Palaia I, Graziano M, Bellati F, Manci N, Angioli R . Intraperitoneal paclitaxel as consolidation treatment in ovarian cancer patients: a case control study. Oncology. 2010; 78(1):20-5. DOI: 10.1159/000287968. View

Agarwal R, Kaye S . Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer. 2003; 3(7):502-16. DOI: 10.1038/nrc1123. View

Bhatt R, Merchan J, Parker R, Wu H, Zhang L, Seery V . A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma. Cancer. 2010; 116(7):1751-6. PMC: 2847062. DOI: 10.1002/cncr.24902. View

10.

Seidman A, Hochhauser D, Gollub M, Edelman B, Yao T, Hudis C . Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J Clin Oncol. 1996; 14(6):1877-84. DOI: 10.1200/JCO.1996.14.6.1877. View

11.

Sako T, Burioka N, Yasuda K, Tomita K, Miyata M, Kurai J . Cellular immune profile in patients with non-small cell lung cancer after weekly paclitaxel therapy. Acta Oncol. 2004; 43(1):15-9. DOI: 10.1080/02841860310016226. View

12.

Klauber N, Parangi S, Flynn E, Hamel E, DAmato R . Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res. 1997; 57(1):81-6. View

13.

Walsh V, Goodman J . From taxol to Taxol: the changing identities and ownership of an anti-cancer drug. Med Anthropol. 2002; 21(3-4):307-36. DOI: 10.1080/01459740214074. View

14.

Vasey P, Jayson G, Gordon A, Gabra H, Coleman R, Atkinson R . Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2004; 96(22):1682-91. DOI: 10.1093/jnci/djh323. View

15.

Zhang D, Yang R, Wang S, Dong Z . Paclitaxel: new uses for an old drug. Drug Des Devel Ther. 2014; 8:279-84. PMC: 3934593. DOI: 10.2147/DDDT.S56801. View

16.

Aggarwal B, Vijayalekshmi R, Sung B . Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res. 2009; 15(2):425-30. DOI: 10.1158/1078-0432.CCR-08-0149. View

17.

Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A . Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res. 2006; 12(4):1317-24. DOI: 10.1158/1078-0432.CCR-05-1634. View

18.

Marchetti P, Urien S, Antonini Cappellini G, Ronzino G, Ficorella C . Weekly administration of paclitaxel: theoretical and clinical basis. Crit Rev Oncol Hematol. 2002; 44 Suppl:S3-13. DOI: 10.1016/s1040-8428(02)00109-9. View

19.

Duan Z, Foster R, Bell D, Mahoney J, Wolak K, Vaidya A . Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin Cancer Res. 2006; 12(17):5055-63. DOI: 10.1158/1078-0432.CCR-06-0861. View

20.

Bristow R, Tomacruz R, Armstrong D, Trimble E, Montz F . Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002; 20(5):1248-59. DOI: 10.1200/JCO.2002.20.5.1248. View